REG - Venture Life Group - Transaction in Own Shares

Venture LifeAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251125:nRSY8083Ia&default-theme=true

RNS Number : 8083I  Venture Life Group PLC  25 November 2025

25 November 2025

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Transaction in Own Shares

 

Venture Life Group plc (AIM: VLG), a recognised leader in proactive healthy
longevity, product innovation, development, and commercialisation within the
global consumer healthcare sector, announces that, in accordance with the
terms of its share buyback programme announced on 30 September 2025, the
Company has purchased 65,479 ordinary shares of 0.3 pence each in the capital
of the Company ("Ordinary Shares") in the market at a volume weighted average
price of 58.21 pence per Ordinary Share through Cavendish Capital Markets
Limited ("Cavendish").

 

The Ordinary Shares acquired will be held as treasury shares.

 

 

Aggregated Information

 

 Date of Purchase:                                               24/11/2025
 Aggregate Number of Ordinary Shares Purchased:                  65,479
 Lowest Price Paid per Ordinary Share (pence):                   58.21
 Highest Price Paid per Ordinary Share (pence):                  58.21
 Volume-Weighted Average Price Paid per Ordinary Share (pence):  58.21

 

 

Following the repurchase of the Ordinary Shares, Venture Life will have
128,052,312 Ordinary Shares in issue, including 291,318 Ordinary Shares held
in treasury.

The total number of voting rights in the Company is therefore 127,760,994.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

 

 Individual Transactions
 Number of Ordinary Shares purchased  Transaction price (pence per Ordinary Share)  Time of transaction  Venue
 65,479                               58.21                                         16:40                AIMX

 

 

For further information, please contact:

Venture Life Group
PLC
                +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSFEWFALEISEFF



            Copyright 2019 Regulatory News Service, all rights reserved